# An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications

> **NCT04322188** · — · COMPLETED · sponsor: **A.O. Ospedale Papa Giovanni XXIII** · enrollment: 220 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection

## Interventions

- **OTHER:** 

## Key facts

- **NCT ID:** NCT04322188
- **Lead sponsor:** A.O. Ospedale Papa Giovanni XXIII
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-19
- **Primary completion:** 2020-05-08
- **Final completion:** 2020-05-08
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2020-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322188, "An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04322188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*